References
- Chow CY, Foster CS. Mooren’s ulcer. Int Ophthalmol Clin. 1996;36(1):1–13. Winter. doi:10.1097/00004397-199603610-00003.
- Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am. 2007;33(4):835–854. doi:10.1016/j.rdc.2007.08.002.
- Li S, Deng Y, Du C, et al. Rapid deterioration of Mooren’s ulcers after conjunctival flap: a review of 2 cases. BMC Ophthalmol. 2017 Jun 15;17(1):93. doi:10.1186/s12886-017-0488-1.
- Chen KH, Hsu WM, Liang CK. Relapsing Mooren’s ulcer after amniotic membrane transplantation combined with conjunctival autografting. Ophthalmology. 2004 Apr;111(4):792–795. doi:10.1016/j.ophtha.2003.06.024.
- Ashar JN, Mathur A, Sangwan VS. Immunosuppression for Mooren’s ulcer: evaluation of the stepladder approach-topical, oral and intravenous immunosuppressive agents. Br J Ophthalmol. 2013 Nov;97(11):1391–1394. doi:10.1136/bjophthalmol-2012-302627.
- Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004 Feb;111(2):352–356. doi:10.1016/S0161-6420(03)00721-8.
- Huerva V, Ascaso FJ, Grzybowski A. Infliximab for peripheral ulcerative keratitis treatment. Medicine (Baltimore). 2014 Nov;93(26):e176. doi:10.1097/MD.0000000000000176.
- Fatima R, Bittar K, Aziz M. Infliximab. 2021 Dec 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan; 1–15. PMID: 29763197.
- Odorcic S, Keystone EC, Ma JJ. Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up. Cornea. 2009 Jan;28(1):89–92. doi:10.1097/ICO.0b013e318181a84f.
- Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and Adalimumab. J Dermatolog Treat. 2004 Sep;15(5):280–294. doi:10.1080/09546630410017275.
- O’Connor M, Buchman A, Marshall G, Anaphylaxislike reaction to infliximab in a patient with Crohn’s disease. Dig Dis Sci 2002 Jun;47(6): 1323–5.
- Menon Y, Cucurull E, Espinoza LR. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology (Oxford) 2003 Oct;42(10): 1273–4.
- A Marchesoni, M Arreghini, B Panni, N Battafarano, L Uziel. Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. Rheumatology (Oxford) 2003 Jan;42 (1): 193–4.
- En Tusscher MP, Jacobs PJ, Busch MJ de Graaf L, Diemont WL. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 2003 Mar;15; 326 (7389):579.
- Mejico LJ, Infliximab-associated retrobulbar optic neuritis.Arch Ophthalmol 2004 122: 793–4.
- Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet. 2001 Nov; 24;358 (9295): 1784.
- Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol 2003 Jul;30(7): 1624–5.
- Tai TL, O’Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford). 2002 Aug;41(8): 951–2.
- Roddy E, Courtney PA, Morris A. Non‐Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology. 2002 Oct;40(10):1194–5.
- Fontana L, Parente G, Neri P, Reta M, Tassinari G. Favourable response to infliximab in a case of bilateral refractory Mooren’s ulcer. Clin Exp Ophthalmol. 2007 Dec;35(9):871–873. doi:10.1111/j.1442-9071.2007.01609.x.
- Saw VP, Cornelius N, Salama AD, Pusey C, Lightman SL. Infliximab therapy for aggressive mooren ulceration. Arch Ophthalmol. 2008 May;126(5):734. doi:10.1001/archopht.126.5.734.
- Meskin SW, Carlson EM. Mooren’s-type ulceration associated with severe hidradenitis suppurativa: a case report and literature review. Ocul Immunol Inflamm. 2011 Oct;19(5):340–342. doi:10.3109/09273948.2011.584653.
- Xia A, Dietrich-Ntoukas T, Pleyer U. Effect of Anti-TNF treatment on Mooren’s ulcer: a case series and review of the literature. Ocul Immunol Inflamm. 2022 Jan 20:1–7. doi:10.1080/09273948.2021.2023581.